肺癌患者-话题@MedSci

#肺癌患者#

303篇内容 | 5542人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1990739, encodeId=11671990e39f5, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, objectType=article, longId=202368, objectId=85c8202368f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c8202368f2, replyNumber=0, likeNumber=83, createdTime=2021-04-04, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c8202368f2, moduleTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c8202368f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990751, encodeId=109f1990e512a, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, objectType=article, longId=208973, objectId=b4c72089e345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4c72089e345, replyNumber=0, likeNumber=72, createdTime=2021-03-27, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4c72089e345, moduleTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4c72089e345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990735, encodeId=1c731990e3510, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证, objectType=article, longId=199086, objectId=e4391990862a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4391990862a, replyNumber=0, likeNumber=80, createdTime=2020-10-31, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4391990862a, moduleTitle=Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4391990862a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990725, encodeId=11751990e2550, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=年老体弱的肺癌患者，特罗凯用多大剂量合适？, objectType=article, longId=195720, objectId=57ab195e2094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57ab195e2094, replyNumber=0, likeNumber=72, createdTime=2020-11-01, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57ab195e2094, moduleTitle=年老体弱的肺癌患者，特罗凯用多大剂量合适？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57ab195e2094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990714, encodeId=9f3d1990e1460, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=赛诺菲和再生元的抗PD-1药物Libtayo显著提高肺癌患者的存活率, objectType=article, longId=193092, objectId=285a193092a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285a193092a3, replyNumber=0, likeNumber=70, createdTime=2020-08-03, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285a193092a3, moduleTitle=赛诺菲和再生元的抗PD-1药物Libtayo显著提高肺癌患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285a193092a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990729, encodeId=c48d1990e29b4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, objectType=article, longId=196602, objectId=6b09196602cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b09196602cb, replyNumber=0, likeNumber=45, createdTime=2020-08-02, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b09196602cb, moduleTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b09196602cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990727, encodeId=e8741990e27ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Clinica Chimica Acta：基于ELISA法检测肺癌患者开放阅读框蛋白1, objectType=article, longId=196298, objectId=759219629834, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=759219629834, replyNumber=0, likeNumber=65, createdTime=2021-03-30, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=759219629834, moduleTitle=Clinica Chimica Acta：基于ELISA法检测肺癌患者开放阅读框蛋白1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=759219629834)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990730, encodeId=258b1990e302c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Sci Rep：肿瘤周围和肿瘤内的放射学特征可以预测肺癌患者的生存结局, objectType=article, longId=196786, objectId=e716196e860c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e716196e860c, replyNumber=0, likeNumber=47, createdTime=2021-02-04, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e716196e860c, moduleTitle=Sci Rep：肿瘤周围和肿瘤内的放射学特征可以预测肺癌患者的生存结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e716196e860c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990726, encodeId=6b911990e265e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=127, createdTime=2020-09-24, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990722, encodeId=12d01990e2227, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=101, createdTime=2021-03-27, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990720, encodeId=01b51990e20b1, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=60, createdTime=2020-10-03, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990711, encodeId=13aa1990e11d7, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, objectType=article, longId=192235, objectId=15911922351b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15911922351b, replyNumber=0, likeNumber=89, createdTime=2020-08-24, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15911922351b, moduleTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15911922351b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990744, encodeId=c1c31990e440c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Eur Radiol：非小细胞肺癌患者前纵隔淋巴结到底有没有转移？, objectType=article, longId=205356, objectId=3f632053564a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f632053564a, replyNumber=0, likeNumber=95, createdTime=2021-06-22, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f632053564a, moduleTitle=Eur Radiol：非小细胞肺癌患者前纵隔淋巴结到底有没有转移？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f632053564a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990749, encodeId=f24b1990e498a, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=中美药企合作成果获批用于肺癌患者一线治疗, objectType=article, longId=206757, objectId=b56f206e570b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b56f206e570b, replyNumber=0, likeNumber=94, createdTime=2021-03-24, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b56f206e570b, moduleTitle=中美药企合作成果获批用于肺癌患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b56f206e570b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990713, encodeId=8a571990e13a9, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=J Bone Oncol：诊断时有骨转移的小细胞肺癌患者的临床结局, objectType=article, longId=192873, objectId=a0001928e3cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0001928e3cf, replyNumber=0, likeNumber=75, createdTime=2020-07-16, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0001928e3cf, moduleTitle=J Bone Oncol：诊断时有骨转移的小细胞肺癌患者的临床结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0001928e3cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, objectType=article, longId=204834, objectId=996020483414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996020483414, replyNumber=0, likeNumber=75, createdTime=2020-12-26, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996020483414, moduleTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996020483414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990704, encodeId=01d41990e04a6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=187720, objectId=ddb118e72078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb118e72078, replyNumber=0, likeNumber=70, createdTime=2020-10-15, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb118e72078, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb118e72078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990734, encodeId=8b461990e34eb, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=75, createdTime=2021-04-08, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990728, encodeId=053f1990e2874, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Chest：晚期肺癌患者临终时姑息治疗与医疗资源使用和治疗质量的关联, objectType=article, longId=196493, objectId=44361964935b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44361964935b, replyNumber=0, likeNumber=45, createdTime=2021-01-20, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44361964935b, moduleTitle=Chest：晚期肺癌患者临终时姑息治疗与医疗资源使用和治疗质量的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44361964935b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990715, encodeId=46591990e15f4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, objectType=article, longId=193124, objectId=e57a19312429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57a19312429, replyNumber=0, likeNumber=58, createdTime=2020-06-14, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57a19312429, moduleTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57a19312429)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肺癌患者

2020-05-29

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗

2021-04-04

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择

2021-03-27

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证

2020-10-31

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

年老体弱的肺癌患者，特罗凯用多大剂量合适？

2020-11-01

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

赛诺菲和再生元的抗PD-1药物Libtayo显著提高肺癌患者的存活率

2020-08-03

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后

2020-08-02

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Clinica Chimica Acta：基于ELISA法检测肺癌患者开放阅读框蛋白1

2021-03-30

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Sci Rep：肿瘤周围和肿瘤内的放射学特征可以预测肺癌患者的生存结局

2021-02-04

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者

2020-09-24

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2021-03-27

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!

2020-10-03

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点

2020-08-24

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Eur Radiol：非小细胞肺癌患者前纵隔淋巴结到底有没有转移？

2021-06-22

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

中美药企合作成果获批用于肺癌患者一线治疗

2021-03-24

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

J Bone Oncol：诊断时有骨转移的小细胞肺癌患者的临床结局

2020-07-16

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究

2020-12-26

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2020-10-15

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2021-04-08

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Chest：晚期肺癌患者临终时姑息治疗与医疗资源使用和治疗质量的关联

2021-01-20

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定

2020-06-14

科室
- - 订阅+
  - 更多科室
工具
服务